Consultant GU Oncology @TheChristieNHS, formerly @royalmarsdenNHS, keen on Football/Aviation/Cats, I draw coloured circles of different diameters for a living
Manchester, England
Joined September 2009
- Tweets1.6K
- Following2.7K
- Followers779
- Likes16.9K
Deep Chakrabarti retweeted
Those sneaky migrants, not only are they lazy and living off benefits, they're also taking all the jobs!
Deep Chakrabarti retweeted
Even 20 years into radiology and medical education, the doubt still surfaces. Imposter syndrome never left me. The difference now is knowing that no one has it all figured out. If you’re willing to learn and adapt with humility, you belong in medicine.
Deep Chakrabarti retweeted
Clearly you did not read the manuscript and have minimal grasp of radiation biology. They used low dose SBRT, which did have improved QOL/reduced toxicity in select domains, but will not show superiority with those doses which are not standard today.
Most people who use that Rx give a 120% hotspot, but they did not even allow dose much over 38 Gy to hotspots!
PACE-B gave Rx of 40 Gy with hotspots over 44 Gy. This may not seem like a lot to you, but it is a big difference.
Hilarious this is coming from the biggest proponent of focal therapy who cant even run a single RCT to prove it helps patients.
Presumably SBRT for localised favourable intermediate PCa will be rolled back following this RCT of 698 patients randomised in 136 international centres; designed and powered a priori as superiority of cancer control for SBRT over MH-IMRT, but wasn’t?
jamanetwork.com/journals/jam…
Deep Chakrabarti retweeted
Have this weird feeling that Gianni Infantino will pull off his mask to reveal Sepp Blatter.
Deep Chakrabarti retweeted
The CO2A sitting is 27 August — about five weeks out.
I'm a consultant & I've put a free FRCR 2A question up at a new page — one a day, every day, until the exam and beyond.
Answer it, then see why every option is right or wrong, with the source named.
frcrvault.com/free-question?…
Deep Chakrabarti retweeted
Just read the new Light et al. focal therapy paper in European Urology. In short: beyond fatally flawed marketing brochure with a DOI. Here's the autopsy 🧵
🚨 NEW IN @EUplatinum! 🚨
The largest analysis of focal therapy by Imperial Prostate and UK colleagues, reporting 1⃣0⃣-year outcomes after focal HIFU and cryotherapy in 3⃣4⃣7⃣7⃣ men 🔥🧊
Led by @AJWLight @LondonProstate1 @TaimurShah
Read for free: europeanurology.com/article/…
Deep Chakrabarti retweeted
Honest title: "In 3,477 Highly Selected, Largely Low-Risk Men With Median 3.3-Year Follow-Up, Focal HIFU/Cryotherapy Resulted in 30% Radical Salvage Rate, With No Comparison to Active Surveillance."
Deep Chakrabarti retweeted
I think we do know when to add an ARPI to radical prostatectomy: Never. No good reason to add drug cost and toxicity when no benefit in OS, QoL or even MFS (by conventional imaging)?
Deep Chakrabarti retweeted
My @ASTRO_org 2026 GU spring refresher extended "long-course" slide deck is available at
drive.google.com/file/d/1xA_…
You can also watch the "short-course" 1.5 hour narrated version here:
nitter.gq/NicholasZaorsky/status…
2026 Genitourinary Oncology Spring Refresher - Dry Run
Updates in the management of cancers of the prostate, bladder, kidney, testes, from @NCCN @ASTRO_org @ESTRO_RT @Uroweb
#Radonc residents @ARRO_org, I hope it helps you ace the board exams!
youtu.be/IOQB79eXWH8
Deep Chakrabarti retweeted
Interesting that partial gland therapies were not even in the trial. Ivermectin may also offer a better alternative.
Perhaps the evidence based conclusion is that active monitoring is the preferred approach based on level 1 data.
Deep Chakrabarti retweeted
I wrote this in a moment I never would have chosen. A sudden pause that made me see my life clearly.
The meaning of our work is profound. This experience simply helped me see more clearly what matters most.
“Time is Finite” JAMA
jamanetwork.com/journals/jam…
Deep Chakrabarti retweeted
Thanks. If I was the patient, I would prefer the STAMPEDE-2 trial, which mandates prostate radiotherapy, and tests the addition of SBRT to the oligomets.
Deep Chakrabarti retweeted
#EAU26 long-term results from randomized ARTO Ph II trial (SBRT + AA vs AA):
• bPFS: 43 vs 17 mo (HR 0.49, p<0.001)
• rPFS: 44 vs 17 mo (HR 0.48, p<0.001)
• OS: NR vs 50 mo (HR 0.55, p=0.02)
• PCSS: NR vs NR (HR 0.37, p=0.006)
Supports Ph 3 trials of met-directed SBRT + systemic Rx in oligomet CRPC @urotoday
Deep Chakrabarti retweeted
😅
🚨 New head-to-head RCT in @NEJM: apixaban vs rivaroxaban 🥊
🏆 Apixaban emerges as the safe winner, with half the risk of bleeding complications
💡 For patients at high risk of GI bleeding, apixaban may be preferrable to rivaroxaban
nejm.org/doi/full/10.1056/NE…
Deep Chakrabarti retweeted
I would stand up, but I need to sit here to finish reading about how sitting is increasing mortality risk.
Deep Chakrabarti retweeted
#GU26 - first visit since COVID. Already bumped into old friends as if I've never been away.
Highlighting a piece by @Hannah_Brom describing why we need to do the #ENHANCE trial - high v low dose ARPI @ProstateUKProfs @CRUKresearch @MCRCnews @ManchesterBRC
dailynews.ascopubs.org/do/re…
Deep Chakrabarti retweeted
This 2025 review article, led by @DeepOnco of @royalmarsdenNHS, outlines global trends and the evolving diagnostics, treatment, and surveillance of #ProstateCancer: acsjournals.onlinelibrary.wi…
@PCaParker @AmarUKishan @VedangMurthy @nickva1 @alison_tree @APCCC_Lugano @ICR_London
